v3.26.3
CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Pre-Funded Warrants
Common Stock Warrants
Common Stock
Common Stock
Pre-Funded Warrants
Common Stock
Common Stock Warrants
Additional Paid-In Capital
Additional Paid-In Capital
Pre-Funded Warrants
Additional Paid-In Capital
Common Stock Warrants
Accumulated Other Comprehensive (Loss) Income
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2024       47,714,708              
Beginning balance at Dec. 31, 2024 $ 79,626     $ 5     $ 461,339     $ 2 $ (381,720)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Exercise of stock options and purchases pursuant to employee stock purchase plan (in shares)       6,859              
Exercise of stock options and purchases pursuant to employee stock purchase plan 8           8        
Issuance of common stock upon settlement of restricted stock units (in shares)       232,076              
Taxes paid related to net share settlement of restricted stock units (in shares)       (54,403)              
Taxes paid related to net share settlement of restricted stock units (65)           (65)        
Unrealized (loss) gain on investments (2)                 (2)  
Stock-based compensation expense 1,721           1,721        
Net loss (13,702)                   (13,702)
Ending balance (in shares) at Mar. 31, 2025       47,899,240              
Ending balance at Mar. 31, 2025 67,586     $ 5     463,003     0 (395,422)
Beginning balance (in shares) at Dec. 31, 2024       47,714,708              
Beginning balance at Dec. 31, 2024 79,626     $ 5     461,339     2 (381,720)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Unrealized (loss) gain on investments 1                    
Net loss (36,216)                    
Ending balance (in shares) at Sep. 30, 2025       63,151,789              
Ending balance at Sep. 30, 2025 93,240     $ 7     511,166     3 (417,936)
Beginning balance (in shares) at Mar. 31, 2025       47,899,240              
Beginning balance at Mar. 31, 2025 67,586     $ 5     463,003     0 (395,422)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Issuance of common stock upon settlement of restricted stock units (in shares)       3,975              
Unrealized (loss) gain on investments 1                 1  
Stock-based compensation expense 1,890           1,890        
Net loss (12,458)                   (12,458)
Ending balance (in shares) at Jun. 30, 2025       47,903,215              
Ending balance at Jun. 30, 2025 57,019     $ 5     464,893     1 (407,880)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Proceeds from sale of common stock, pre-funded warrants and common stock warrants, net of offering costs (in shares)       15,225,158              
Proceeds from sale of common stock, pre-funded warrants and common stock warrants, net of offering costs 44,480     $ 2     44,478        
Exercise of stock options and purchases pursuant to employee stock purchase plan (in shares)       23,416              
Exercise of stock options and purchases pursuant to employee stock purchase plan 17           17        
Unrealized (loss) gain on investments 2                 2  
Stock-based compensation expense 1,778           1,778        
Net loss (10,056)                   (10,056)
Ending balance (in shares) at Sep. 30, 2025       63,151,789              
Ending balance at Sep. 30, 2025 93,240     $ 7     511,166     3 (417,936)
Beginning balance (in shares) at Dec. 31, 2025       63,279,843              
Beginning balance at Dec. 31, 2025 82,390     $ 7     512,906     6 (430,529)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Proceeds from sale of common stock, pre-funded warrants and common stock warrants, net of offering costs (in shares)       5,000,000              
Proceeds from sale of common stock, pre-funded warrants and common stock warrants, net of offering costs 20,562           20,562        
Exercise of common stock warrants into common stock and pre-funded warrants (in shares)         6,928,891 153,664          
Exercise of common stock warrants into common stock and pre-funded warrants     $ 5,444           $ 5,444    
Exercise of stock options and purchases pursuant to employee stock purchase plan (in shares)       68,916              
Exercise of stock options and purchases pursuant to employee stock purchase plan 59           59        
Issuance of common stock upon settlement of restricted stock units (in shares)       206,513              
Taxes paid related to net share settlement of restricted stock units (in shares)       (56,040)              
Taxes paid related to net share settlement of restricted stock units (262)           (262)        
Unrealized (loss) gain on investments (6)                 (6)  
Stock-based compensation expense 2,415           2,415        
Net loss (14,767)                   (14,767)
Ending balance (in shares) at Mar. 31, 2026       75,581,787              
Ending balance at Mar. 31, 2026 95,835     $ 7     541,124     0 (445,296)
Beginning balance (in shares) at Dec. 31, 2025       63,279,843              
Beginning balance at Dec. 31, 2025 82,390     $ 7     512,906     6 (430,529)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Proceeds from sale of common stock, pre-funded warrants and common stock warrants, net of offering costs (in shares)   7,870,624                  
Exercise of common stock warrants into common stock and pre-funded warrants (in shares)   45,805,922 6,701,370                
Unrealized (loss) gain on investments (68)                    
Net loss (55,123)                    
Ending balance (in shares) at Sep. 30, 2026       101,833,213              
Ending balance at Sep. 30, 2026 193,662     $ 10     679,365     (62) (485,651)
Beginning balance (in shares) at Mar. 31, 2026       75,581,787              
Beginning balance at Mar. 31, 2026 95,835     $ 7     541,124     0 (445,296)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Proceeds from sale of common stock, pre-funded warrants and common stock warrants, net of offering costs (in shares)       13,691,876              
Proceeds from sale of common stock, pre-funded warrants and common stock warrants, net of offering costs 80,198     $ 1     80,197        
Exercise of common stock warrants into common stock and pre-funded warrants (in shares)         4,825,575 6,547,607          
Exercise of common stock warrants into common stock and pre-funded warrants   $ 0 $ 47,335   $ 1 $ 1   $ (1) 47,334    
Exercise of stock options and purchases pursuant to employee stock purchase plan (in shares)       76,170              
Exercise of stock options and purchases pursuant to employee stock purchase plan 257           257        
Issuance of common stock upon settlement of restricted stock units (in shares)       3,975              
Taxes paid related to net share settlement of restricted stock units (in shares)       (968)              
Taxes paid related to net share settlement of restricted stock units (7)           (7)        
Unrealized (loss) gain on investments (63)                 (63)  
Stock-based compensation expense 2,733           2,733        
Net loss (15,152)                   (15,152)
Ending balance (in shares) at Jun. 30, 2026       100,726,022              
Ending balance at Jun. 30, 2026 211,136     $ 10     671,637     (63) (460,448)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Proceeds from sale of common stock, pre-funded warrants and common stock warrants, net of offering costs (73)           (73)        
Exercise of common stock warrants into common stock and pre-funded warrants (in shares)         1,000,305            
Exercise of common stock warrants into common stock and pre-funded warrants     $ 4,166           $ 4,166    
Exercise of stock options and purchases pursuant to employee stock purchase plan (in shares)       106,886              
Exercise of stock options and purchases pursuant to employee stock purchase plan 336           336        
Unrealized (loss) gain on investments 1                 1  
Stock-based compensation expense 3,299           3,299        
Net loss (25,203)                   (25,203)
Ending balance (in shares) at Sep. 30, 2026       101,833,213              
Ending balance at Sep. 30, 2026 $ 193,662     $ 10     $ 679,365     $ (62) $ (485,651)